Protection of Renal Impairment by Angiotensin II Type 1 Receptor Blocker in Rats with Post-Infarction Heart Failure

REFERENCES

• Lekawanvijit S, Kompa AR, Zhang Y, Wang BH, Kelly DJ, Krum H. Myocardial infarction impairs renal function, induces renal interstitial fibrosis and increases renal kim-1 expression: implications for cardiorenal syndrome. Am J Physiol Heart Circ Physiol. 2012;302(9):H1884–H1893.
   PubMed Web of Science ®Google Scholar
• Mashima Y, Konta T, Ichikawa K, Rapid decline in renal function after acute myocardial infarction. Clin Nephrol. 2012;79:15–20.
   Web of Science ®Google Scholar
• Liang KV, Williams AW, Greene EL, Redfield MM. Acute decompensated heart failure and the cardiorenal syndrome. Crit Care Med. 2008;36(1 Suppl):S75–S88.
   PubMedGoogle Scholar
• Schunkert H, Tang SS, Litwin SE, Regulation of intrarenal and circulating renin-angiotensin systems in severe heart failure in the rat. Cardiovasc Res. 1993;27(5):731–735.
   PubMed Web of Science ®Google Scholar
• Hillege HL, van Gilst WH, van Veldhuisen DJ, Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ace inhibition: the cats randomized trial. Eur Heart J. 2003;24(5):412–420.
   PubMed Web of Science ®Google Scholar
• Windt WA, Eijkelkamp WB, Henning RH, Renal damage after myocardial infarction is prevented by renin-angiotensin-aldosterone-system intervention. J Am Soc Nephrol. 2006;17(11):3059–3066.
   PubMed Web of Science ®Google Scholar
• Zheng S, Zhou C, Weng Y, Improvements of cardiac electrophysiologic stability and ventricular fibrillation threshold in rats with myocardial infarction treated with cardiac stem cells. Crit Care Med. 2011;39(5):1082–1088.
   PubMed Web of Science ®Google Scholar
• Cai MY, Hou JH, Rao HL, High expression of h3k27me3 in human hepatocellular carcinomas correlates closely with vascular invasion and predicts worse prognosis in patients. Mol Med. 2011;17(1–2):12–20.
   PubMed Web of Science ®Google Scholar
• va Dokkum RP, Eijkelkamp WB, Kluppel AC, Myocardial infarction enhances progressive renal damage in an experimental model for cardio-renal interaction. J Am Soc Nephrol. 2004;15(12):3103–3110.
   PubMed Web of Science ®Google Scholar
• Windt WA, Henning RH, Kluppel AC, Xu Y, de Zeeuw D, van Dokkum RP. Myocardial infarction does not further impair renal damage in 5/6 nephrectomized rats. Nephrol Dial Transplant. 2008;23(10):3103–3110.
   PubMed Web of Science ®Google Scholar
• Lassus J, Harjola VP. Cystatin c: a step forward in assessing kidney function and cardiovascular risk. Heart Fail Rev. 2012;17(2):271–282.
   PubMed Web of Science ®Google Scholar
• Lassus JP, Nieminen MS, Peuhkurinen K, Markers of renal function and acute kidney injury in acute heart failure: definitions and impact on outcomes of the cardiorenal syndrome. Eur Heart J. 2010;31(22):2791–2798.
   PubMed Web of Science ®Google Scholar
• Homma T, Sonoda H, Manabe K, Activation of renal angiotensin type 1 receptor contributes to the pathogenesis of progressive renal injury in a rat model for chronic cardiorenal syndrome. Am J Physiol Renal Physiol. 2012;302(6):F750–F761.
   PubMed Web of Science ®Google Scholar
• Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007;59(3):251–287.
   PubMed Web of Science ®Google Scholar
• Wang CT, Zou LX, Navar LG. Renal responses to at1 blockade in angiotensin ii-induced hypertensive rats. J Am Soc Nephrol. 1997;8(4):535–542.
   PubMed Web of Science ®Google Scholar
• Bock JS, Gottlieb SS. Cardiorenal syndrome: new perspectives. Circulation. 2010;121(23):2592–2600.
   PubMed Web of Science ®Google Scholar
• Koc Y, Mazi E, Sakaci T, Effect of olmesartan on serum cystatin c levels in the patients with essential hypertension. Eur Rev Med Pharmacol Sci. 2011;15(12):1389–1394.
   PubMed Web of Science ®Google Scholar
• Watanabe S, Okura T, Kurata M, Valsartan reduces serum cystatin c and the renal vascular resistance in patients with essential hypertension. Clin Exp Hypertens. 2006;28(5):451–461.
   PubMed Web of Science ®Google Scholar
• Albayrak S, Ordu S, Ozhan H, Effect of olmesartan medoxomil on cystatin c level, left ventricular hypertrophy and diastolic function. Blood Press. 2009;18(4):187–191.
   PubMed Web of Science ®Google Scholar
• Izuhara Y, Nangaku M, Inagi R, Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol. 2005;16(12):3631–3641.
   PubMed Web of Science ®Google Scholar
• Matavelli LC, Huang J, Siragy HM. Angiotensin at (2) receptor stimulation inhibits early renal inflammation in renovascular hypertension. Hypertension. 2011;57(2):308–313.
   PubMed Web of Science ®Google Scholar
• Naito T, Ma LJ, Yang H, Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis. Am J Physiol Renal Physiol. 2010;298(3):F683–F691.
   PubMed Web of Science ®Google Scholar